Abstract: Provided is an electrode catheter whose movable shape has a high reproducibility even when the load changes, and has a high degree of freedom in corresponding to the shape of a measurement site.

Abstract: Provided is a multiple-electrode monorail guide catheter for use in vascular insertion, including: an elongated catheter main body having a proximal end and a distal end; a guidewire inlet opening on the distal end; a guidewire outlet opening; an operation tube; a terminal unit on the proximal end; an electrode assembly having a double-lumen structure composed of an outer tube having electrodes on an outer surface of the outer tube and an inner tube independently provided from the outer tube, allowing insertion of a guidewire, having an outer diameter smaller than an inner diameter of the outer tube, and being accommodated within an outer tube lumen; a clearance defined by the outer tube luminal surface and an inner tube outer circumferential surface; and lead wires extending from the electrodes to the terminal unit on the proximal end and being inserted into the lumen of the outer tube.

Abstract: Provided is a multiple-electrode monorail guide catheter for use in vascular insertion, including: an elongated catheter main body having a proximal end and a distal end; a guidewire inlet opening on the distal end; a guidewire outlet opening; an operation tube; a terminal unit on the proximal end; an electrode assembly having a double-lumen structure composed of an outer tube having electrodes on an outer surface of the outer tube and an inner tube independently provided from the outer tube, allowing insertion of a guidewire, having an outer diameter smaller than an inner diameter of the outer tube, and being accommodated within an outer tube lumen; a clearance defined by the outer tube luminal surface and an inner tube outer circumferential surface; and lead wires extending from the electrodes to the terminal unit on the proximal end and being inserted into the lumen of the outer tube.

Abstract: A system for providing granular functionality called web services to commercial customers includes a web server configured to accept service requests from software application clients, functional implementations of the services, and a means of accounting for usage. The service grid architecture makes practical a reliable commercial provider of web services in the face of unreliable sources of functional implementations. This is accomplished through the commoditization of multiple implementation sources per service, standard forms for each service to which a plurality of sources is adapted, and a rules based approach to source selection per service call.

Abstract: The present disclosure details a thermoacoustic driven compressor having a pressurized housing, which contains within a thermoacoustic engine and a working gas, coupled to a positive displacement reciprocating compressor. The thermoacoustic driven compressor generates scalable compressed air from a given heat source.

Abstract: A system for providing granular functionality called web services to commercial customers includes among other things a client to issue service requests and receive responses, a web server configured to accept and process service requests, and a means of accounting for usage. The current art specifies standards for functional interactions between web service clients and servers. A set of commercial extensions are defined herein to enable maintenance interactions. This “maintenance protocol” includes operations such as client software that is self-updating in response to server changes and the capability of reconciling client usage logs with service provider invoicing.

Abstract: The present disclosure details a thermoacoustic driven compressor having a pressurized housing, which contains within a thermoacoustic engine and a working gas, coupled to a positive displacement reciprocating compressor. The thermoacoustic driven compressor generates scalable compressed air from a given heat source.

Abstract: A system for providing granular functionality called web services to commercial customers includes a web server configured to accept service requests from software application clients, functional implementations of the services, and a means of accounting for usage. The service grid architecture makes practical a reliable commercial provider of web services in the face of unreliable sources of functional implementations. This is accomplished through the commoditization of multiple implementation sources per service, standard forms for each service to which a plurality of sources is adapted, and a rules based approach to source selection per service call.

Abstract: A system for providing granular functionality called web services to commercial customers includes among other things a client to issue service requests and receive responses, a web server configured to accept and process service requests, and a means of accounting for usage. The current art specifies standards for functional interactions between web service clients and servers. A set of commercial extensions are defined herein to enable maintenance interactions. This “maintenance protocol” includes operations such as client software that is self-updating in response to server changes and the capability of reconciling client usage logs with service provider invoicing.

Abstract: An evaluation device for evaluating the operability of an object device based on the operation of the object device by an examinee, comprising a means of defining the initial status of the above object device, a means of defining a target status after the operation of the object device, an operation identifying means for identifying the operation by the examinee of the object device, a status identifying means for identifying the operation status of the object device by the above operation, a means for judging whether or not the above operation status agrees with a target status, and a clock means for measuring elapsed time required for the above operation status to migrate from an initial status to a target status.

Abstract: Analogues of the Kunitz Protease Inhibitor (KPI) domain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, Xa, XIa, and XIIa. Pharmaceutical compositions containing the KPI analogues, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these analogues and systems for expression of the peptides of the invention are provided.

Abstract: An evaluation device for evaluating the operability of an object device based on the operation of the object device by an examinee & comma; comprising a means of defining the initial status of the above object device & comma; a means of defining a target status after the operation of the object device & comma; an operation identifying means for identifying the operation by the examinee of the object device & comma; a status identifying means for identifying the operation status of the object device by the above operation & comma; a means for judging whether or not the above operation status agrees with a target status & comma; and a clock means for measuring elapsed time required for the above operation status to migrate from an initial status to a target status & period;

Abstract: The invention relates to the design, construction and use of eukaryotic cell lines useful in the identification of inhibitors of &bgr;-amyloid processing. More specifically, the invention relates to in vitro assays capable of identifying or quantifying a 4.2 kDa &bgr;-amyloid protein. The present invention also provides for DNA and protein molecules for the design, construction and use of eukaryotic cell lines useful in the identification of inhibitors of &bgr;-amyloid processing.

Abstract: Analogues of the Kunitz Protease Inhibitor (KPI) domain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, Xa, XIa, and XIIa. Pharmaceutical compositions containing the KPI analogues, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these analogues and systems for expression of the peptides of the invention are provided.

Abstract: Disclosed are heparin binding mitogens which include an epidermal growth factor-homologous segment (HB-EHM). These factors stimulate proliferation of fibroblast cells, epithelial cells, and smooth muscle cells, but not endothelial cells. Also disclosed are isolated antibodies that recognize, and purified nucleic acids that encode, the above growth factors as well as isolated polypeptides, vectors containing such nucleic acids, and cells harboring such vectors. Growth factors of this invention may be used for accelerating the rate of wound healing, for the in vitro culture of HB-EHM-responsive cells, and for the identification of antagonists to HB-EHM.

Abstract: Disclosed are heparin binding mitogens which include an epidermal growth factor-homologous segment (HB-EHM). These factors stimulate proliferation of fibroblast cells, epithelial cells, and smooth muscle cells, but not endothelial cells. Also disclosed are isolated antibodies that recognize, and purified nucleic acids that encode, the above growth factors as well as isolated polypeptides, vectors containing such nucleic acids, and cells harboring such vectors. Growth factors of this invention may be used for accelerating the rate of wound healing, for the in vitro culture of HB-EHM-responsive cells, and for the identification of antagonists to HB-EHM.

Abstract: Antibodies which react with the human phospholipase inhibitory protein/apolipoprotein AIV complex and hPIP are provided.

Abstract: Pseudopeptide compounds based on a modified bradykinin sequence are potent bradykinin receptor antagonists. All or a portion of the amino acids at postions 2 through 5 of the bradykinin sequence are replaced by 2-pyrrolidinyl and/or amino-alkanoic acid or related olefinic derivatives to reduce the peptidic nature of the compounds.The analogs produced are useful in treating conditions and diseases of a mammal and human in which an excess of bradykinin or related kinins are produced or injected such as by insect bites.

Abstract: Cyclic compounds based on a modified bradykinin sequence are potent bradykinin receptor antagonists. Amino acid substitutions are made at postions 2 and 5 or 6 to facilitate the cyclization of the peptide through covalent bonding of the amino acid side chains.The analogs produced are useful in treating conditions and diseases of a mammal and human in which an excess of bradykinin or related kinins are produced or injected such as by insect bites.

Abstract: A new and distinct cultivar of Penstemon plant characterized by medium size red purple flowers in dense clusters, long bloom time, a compact, upright, well branched habit, with multiple crown from the base, clean-looking, deep green, attractive foliage, and excellent vigor.